Fulcrum Therapeutics (FULC) announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application submission and preparing for commercial launch. Ms. Kalofonos joins Fulcrum from ImmunoGen where she served as Senior Vice President and Chief Commercial Officer. Most recently, Ms. Faulds served as SVP, Regulatory Affairs at Alkermes (ALKS)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum’s REACH trial can hit primary endpoint, says Oppenheimer
- Fulcrum Therapeutics expects cash to fund operations into 2027
- Fulcrum Therapeutics reports Q2 EPS 87c, consensus (1c)